In order to improve clinical feasibility, the next generation of NP systems must have controlled biodistribution, reduced toxicity, and be administered less frequently (enhancing patient compliance)
doi: 10.1210/endrev/bnaa011 12 FadiniG
2025: What Has Changed The protocol you would have received in 2025 is not the same protocol we run in 2026, and that is a good thing
Dave Asprey, founder of Bulletproof and a prominent biohacker, has discussed 5-Amino-1MQ in combination with other peptides, highlighting "a lot of buzz about this peptide especially in combination with the 5-amino 1MQ."[28] He suggests it for biohackers seeking metabolic hacks without extreme diets
Stability half-lives were determined assuming a normal single phase exponential decay using Prism 5 graphical/statistical program (GraphPad, San Diego, Calif.)
The guy was doing PT on me